Company InformationStuart Therapeutics is based in Stuart, Florida, USA. The number of employees in Stuart Therapeutics is unknown. Stuart therapeutics is a biotechnology company that offers polycol, a therapeutic platform for ophthalmic indications.
Funding & investorsStuart Therapeutics has received 1 rounds of venture funding. The total funding amount is around $11M.
- BioBrit (Private equity firm)
- InFocus Capital Partners (Micro vc)
- MiMo Capital
- Wisconsin Alumni Research Foundation (University program)
Similar Companies [beta]
Active Venture Investors
Stuart Therapeutics - Blog
- Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital
- Stuart Therapeutics Wins the AdvanSE Life Sciences Conference PitchRounds Competition
- Stuart Therapeutics, Inc. Announces Presentation at ARVO 2020
- Stuart Therapeutics, Inc. Announces Pro-Neuronal Growth Results Using PolyColTM Collagen Mimetic Peptides
- Stuart Therapeutics, Inc. Announces a Strategic Partnership with Ora, Inc.
- Stuart Therapeutics Announces Positive Retinal Indication in vitro Results for PolyCol
Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led by InFocus Capital Partners, an ophthalmology-focused life sciences venture capital fund, with significant participation by the Wisconsin
November 13th, 2020, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that the company’s presentation at the Southeast Life Sciences AdvanSE Life Sciences Conference was judged the winner of the PitchRounds Competition. The competition drew applications from over 70 applications. Twenty companies were selected
Stuart Therapeutics, Inc. (STUART), the leader in the application of collagen mimetic peptide (CMP) technology for ophthalmology, today announced that it has been selected as a presenter at the Association for Research of Vision and Ophthalmology (ARVO) 2020 Annual Meeting in Baltimore, Maryland, May 3rd through 7th at the Baltimore Convention Center. The presentation is
STUART, FLORIDA November 11th, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical therapeutic development company, today announced that it has successfully completed in vitro pro-neuronal growth experiments utilizing the company’s PolyColTM (PolyCol) peptide. PolyCol demonstrated a strong propensity to encourage neurite outgrowth from dorsal root ganglia nerve cells in a model designed to mirror damage
STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization. ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting
April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD).